Nectar Lifesciences Limited specializes in Pharmaceuticals within the Healthcare sector.
Nectar Lifesciences Limited, with Security Code 532649, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Date Begin | Date End | Net Sales | Net Profit | Total Income | Diluted EPS for continuing operation | Other Expenses | Other Income | Depreciation and amortisation expense | Profit (+)/ Loss (-) from Ordinary Activities before Tax |
|---|---|---|---|---|---|---|---|---|---|
| 2024-01-01 | 2024-03-31 | 4,413.74 | 5.92 | 4,428.43 | 0.03 | -610.04 | 14.68 | -147.00 | 111.13 |
| 2024-01-01 | 2024-03-31 | 4,413.74 | 5.99 | 4,428.43 | 0.03 | -609.97 | 14.68 | -147.00 | 111.20 |
| 2023-10-01 | 2023-12-31 | 4,521.71 | 15.67 | 4,526.51 | 0.07 | -609.95 | 4.80 | -153.74 | 24.57 |
| 2023-10-01 | 2023-12-31 | 4,521.71 | 15.67 | 4,526.51 | 0.07 | -609.95 | 4.80 | -153.74 | 24.57 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | -10% |
| 3 Years: | 3% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -22% |
| 5 Years: | -36% |
| 3 Years: | 28% |
| TTM: | 108% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 17% |
| 3 Years: | -8% |
| 1 Year: | 57% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | -10% |
| 3 Years: | 3% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -22% |
| 5 Years: | -36% |
| 3 Years: | 28% |
| TTM: | 108% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 17% |
| 3 Years: | -8% |
| 1 Year: | 57% |
Drug firm Nectar Lifesciences on Tuesday reported a 16.62 per cent decline in its consolidated net profit to Rs 118.03 crore for the third quarter ended December 2022.
Nectar Lifesciences on Monday said it has received final approval from the US health regulator for its generic version of heart drug Ivabradine Hydrochloride tablets.
Drug firm Nectar Lifesciences on Tuesday reported a 13.31 per cent decline in its consolidated net profit to Rs 133.06 crore for the second quarter ended September 2022.
